Eleven Therapeutics

Eleven Therapeutics is a pioneer in the 'TechBio' space, developing a new modality called xRNA—rationally designed mRNA molecules that incorporate chemical modifications to solve delivery, durability, and efficacy challenges. The company integrates massively parallel combinatorial chemistry with deep learning algorithms to map the structure-activity relationship (SAR) of RNA molecules, transforming drug discovery into a programmable process. Headquartered across three global hubs in Cambridge (UK), Tel Aviv (Israel), and Boston (USA), the company leverages its TERA™ and DELiveri™ platforms to identify optimal therapeutic candidates. Their approach is particularly focused on overcoming the limitations of traditional mRNA, such as short half-life and lack of tissue-specific delivery, with an initial emphasis on respiratory and cardiometabolic diseases.